Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




AI Tool Automates Validation of Laboratory Software Configuration Changes

By LabMedica International staff writers
Posted on 20 May 2026

Regulated laboratories face heavy documentation and requalification demands when software configurations change, slowing improvements and discouraging beneficial updates. More...

A new capability now automates planning, execution, and audit-ready documentation for configuration changes in regulated laboratory systems.

Labbit (Vancouver, BC, Canada) has introduced the Validation Assistant as the latest addition to its change management lifecycle for regulated laboratories. Building on the Configuration Assistant unveiled in 2025, the artificial intelligence (AI)-powered feature targets the most time-consuming elements of revalidation. The capability is designed to help laboratories manage system changes more efficiently without sacrificing control or system validation status.

When a new Labbit configuration is created, the Validation Assistant detects what has changed and automatically generates the corresponding test plan, test scenarios, and scripts from the configuration version. It then executes the qualification run and assembles an audit-ready documentation package. The package includes the configuration specification, test plan, execution log, and a summary report to support traceability and minimize manual documentation effort.

The new capability streamlines qualification of configuration updates before deployment to production by generating and executing validation assets directly from the system configuration. It addresses a longstanding bottleneck that has required extensive manual revalidation activities prior to changes being promoted. Labbit will showcase the Validation Assistant at booth 518 during the Bio-IT World Conference & Expo in Boston from May 19 to 21, with live demonstrations of automated documentation workflows for configuration changes.

“Validating a configured piece of software in a regulated lab can be as much work as configuration itself – sometimes even more. Labs have spent years managing configuration risk by limiting change, because every update can create a significant documentation and requalification burden. With the Validation Assistant, we’re applying AI to a very specific operational problem: generating and executing validation assets directly from the system configuration itself,” said Peter Smith, CEO of Labbit.

“In a market where there’s a lot of broad discussion around AI, we think this is a good example of practical AI that addresses a real bottleneck in laboratory operations,” added Smith.

Related Links
Labbit


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Manual Pipetting Aid
Pipette Controllers macro
Gold Member
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Study design and workflow (Parankusham H, Vanderlip C, Birkenbihl C, et al. A two-stage plasma biomarker algorithm reduces amyloid PET use and the p-Tau217 gray zone. Annals of Clinical and Translational Neurology. Published online October 19, 2026. doi:10.1002/acn3.70560)

Two-Step Blood Testing Approach Reduces Uncertainty in Amyloid Assessment

Blood-based biomarkers offer a more accessible, less expensive way to detect Alzheimer’s-related brain changes than traditional methods such as amyloid-beta positron emission tomography (Aβ-PET).... Read more

Molecular Diagnostics

view channel
Image: Tumor DNA is extracted from a pathology sample, and normal DNA is extracted from the buffy coat. Both samples undergo WGS to generate the patient-specific mutational signature. At each follow-up, ctDNA extracted from plasma undergoes WGS and is analyzed using a patient-derived signature and an artificial intelligence (AI) pattern recognition algorithm. FFPE: formalin fixed, paraffin embedded. (Snuderl M, Smadbeck J, Wilkins R, et al. The Journal of Molecular Diagnostics, 2026. DOI: 10.1016/j.jmoldx.2026.07.003)

Liquid Biopsy Detects Lung Cancer Recurrence Signals Months Before Imaging

Non-small cell lung cancer (NSCLC) is the most common type of lung cancer and remains a major cause of cancer-related death. Early-stage tumors are often treated surgically, but recurrence can still occur... Read more

Immunology

view channel
Image Credit: iStock

Antibody Profiling Predicts Inflammatory Bowel Disease Years Before Diagnosis

Inflammatory bowel disease (IBD), which includes Crohn’s disease and ulcerative colitis, involves abnormal immune responses that cause persistent inflammation and damage in the digestive system.... Read more

Pathology

view channel
Image: HETA Quality Control identifies slide quality issues before analysis, while HETA Tumor Detect annotates tumor regions and flags slides likely to contain tumor during scanning. (Photo courtesy of Aignostics)

AI Pathology Platform Targets Workflow Delays and Molecular Test Failures

Pathology laboratories often rely on visual review of tissue slides to assess quality, identify tumors, count mitoses, and estimate tumor content. These tasks can be time-consuming and vary between readers,... Read more

Industry

view channel
Image: The acquisition of Reveal Genomics would expand Hologic’s oncology diagnostics portfolio to support treatment decisions for more women with breast cancer.

Hologic to Broaden Breast Cancer Testing Portfolio Through Reveal Genomics Acquisition

Hologic (Marlborough, MA, USA) has signed a definitive agreement to acquire Reveal Genomics (Barcelona, Spain), a precision oncology company developing genomic diagnostic tests to help personalize cancer treatment.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.